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Background: Cystic fibrosis is caused by mutations of the Cystic Fibrosis Transmembrane conductance Regulator gene (CFTR). Among the 1795
reported mutations, 221 (12.31%) are believed to affect pre-mRNA splicing. Nevertheless, not all splicing mutations have been demonstrated, by
functional assays, to affect splicing in living cells.
Methods: We have used a minigene-based approach, coupled to site-specific mutagenesis, to analyze the effects of presumptive pre-mRNA
splicing mutations.
Results: We show here that the intron 11 1811+1GNC and the intron 12 1898+3ANG mutations strongly affected CFTR pre-mRNA splicing. The
encoded proteins are predicted to be defective, which would thus participate in the disease phenotype of carrier individuals.
Conclusions: These results further validate the minigene strategy for the study of presumptive splice mutations, and report unanticipated defects in
splicing. Such assays should improve the analysis of genotype–phenotype correlations.
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Cystic fibrosis (CF) is caused by mutations of the CFTR gene,
which encodes a chloride transporter protein. CF is the most
frequent autosomal recessive genetic disease, with 1 in 3000
affected carrier individuals. The delta F508 (F508del) mutation is
the most frequent, as it accounts for roughly 70% of the mutant
alleles. Disease severity depends, in part, on the nature of the
mutation that may be present on the other allele. Among the 1795
reportedmutations, 221 (12.31%) are believed to affect pre-mRNA
splicing, but the demonstration of a functional effect has not been
systematically obtained. Several methods can be used to look for
potential pre-mRNA splicing defects, including direct mRNA⁎ Corresponding author. Tel.: +33 2 98 01 83 01; fax: +33 2 98 01 83 22.
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doi:10.1016/j.jcf.2010.12.008analysis from patient samples, analysis of mRNA isolated from
immortalized lymphocytes orminigene assays [1]. In this study, we
have chosen to analyze, with aminigene approach, the effect of two
intronic splice site mutations, one in intron 11 (1811+1GNC) and
one in intron 12 (1898+3ANG) associated with phenotypes of
rather distinct severities.
The 1811+1GNC mutation has been previously described by
Petreska et al. [2]. This mutation was either associated with the
deltaF508 (18/204), with non-deltaF508 (82/204) or with
normal (104/204) chromosomes. The young patient who carried
the deltaF508 mutation on the other chromosome showed
malnutrition due to malabsorption, bilateral bronchopneumonia
with a compensatory emphysema, early manifested anemia,
extremely high sweat C1- values (240 mmole L−1), pancreatic
insufficiency and positive Pseudomonas aeruginosa coloniza-
tion. In Brest, two young subjects, one girl and one boy, were
also diagnosed (in 1996) with both the 1811+1GNC mutationd by Elsevier B.V. All rights reserved.
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120 and 110 mmole L−1 and pancreatic insufficiency. Hence in
all three cases, the severity of the disease was quite strong.
The 1898+3ANG mutation was detected in one female
subject at age 20, with a severe 3659delC frameshift mutation
on the other allele. She showed a 96 mmol L−1 sweat Cl- value
and pancreatic sufficiency. Hence, the severity of the phenotype
was relatively mild.
We used a minigene that had been previously validated to
provide a good matrix with which to assay splicing modifications
[3–6]. The results presented herein demonstrate that the intron 11
1811+1GNCmutation indeed affected CFTR pre-mRNA splicing
with a complex pattern of anomalies, including strongly reduced
levels of correctly spliced transcript, exon exclusion and partial
intron retention. The intron 12 1898+3ANG mutation led to full
skipping of exon 12. Protein structure prediction from the
corresponding transcripts suggested that bothmutations would be
expected to encode aberrant proteins most probably lacking
chloride channel function.
2. Materials and methods
The minigene construct used has been described previously
[7,8]. In order to clone the fragment of interest, genomic DNA
from a healthy subject was extracted and used for PCR
amplification using primers from sites within the 3′ portion of
intron 10 or 11 and the 5′ portion of intron 11 or 12. The primers
were engineered to contain NdeI restriction sites (sequences on
request). The resulting fragment was first cloned into the PCR
Topo2.1 plasmid (Invitrogen) and the sequence was verified
using the Big Dye terminator cycle sequencing kit (Applied
Biosystems) and an ABI 3100 Genetic Analyzer (Applied
Biosystems). It was then removed with the NdeI restriction
enzyme, cloned into the minigene insertion vector and
sequenced again for orientation analysis. Two different
strategies were used to generate the minigenes carrying the
mutations of interest: a—the same strategy as for the WT
minigene but using the mutant genomic DNA as a PCR
template, or b—introducing the mutations by site-directed
mutagenesis (QuikChange II XL Site-Directed Mutagenesis,
Stratagene). The 1811+1GNC and the 1898+3ANG mutations
were selected to design mutant minigene constructs, which were
then used to transfect HeLa cells transiently with the
Lipofectamine 2000 reagent (Invitrogen). The cells were then
incubated for 24 h and harvested to prepare total RNA. The
structure of the amplicons was analyzed by RT-PCR (OneStep
RT-PCR kit, Qiagen) and the products were gel purified
(NucleoSpin extract, Macherey-Nagel) and sequenced. The
procedure outline is shown in Fig. 1.
3. Results
The minigene strategy for pre-mRNA splicing analysis has
been validated previously [9]. Following plasmid transfection in
HeLa cells, which have been commonly used for pre-mRNA
splicing analysis [10], the WT minigene centred on exon 11
showed a strong cDNA band corresponding to the normalinclusion of exon 11, with no detectable exclusion (Fig. 2a). By
contrast, the mutant (1811+1GNC) minigene showed only little
exon 11 inclusion with both a slower and a higher mobility
bands in higher amounts. The cDNA products were sequenced
and, while the correctly sized band was identical with that from
the WT minigene, the lower band showed complete exon 11
skipping while the upper band showed partial intron 11
retention (Fig. 2b). Usage of the donor splice site was shifted
towards the 3′ end (as shown by the arrow in the lower part of
the figure) of the CFTR sequence. Translation of the encoded
sequences showed that the resulting proteins were likely to be
non functional, as a stop codon appeared early in the reading
frame (Fig. 2c).
The second mutation (1898+3ANG) also drove aberrant
CFTR mRNA production, with a full skipping of exon 12
(Fig. 3a). A defective protein was also predicted from sequence
analysis, although in this case, it was not truncated but internally
deleted (Fig. 3b).
4. Discussion
These analyses demonstrate that the minigene strategy could
functionally detect the effects of these CFTR mutations, which
were either anticipated (1811+1GNC) or not (1898+3ANG) to
be splicing mutations. In addition, quite striking results were
obtained.
Concerning the 1811+1GNC mutation, which was located in
the invariant donor splice site (+1) and was thus supposed to
fully prevent splicing, we observed, surprisingly, alternative
splicing events with three distinct mRNAs including correctly
spliced mRNA, albeit in strongly diminished amounts (in a 20
to 1 ratio, as determined by densitometry analysis), when
compared to the wild type control. We believe that this last
observation might be related to the high sensitivity of the
approach. Indeed, the minigene strategy allows analyzing
mRNA expression from high copy numbers of transfected
plasmids, which translate into multiple mRNA copies detect-
able by RT-PCR. Hence, it can be proposed that such a mutation
might not be incompatible with production of splicing at the
right position, provided that it is possible to detect low mRNA
levels. The other two transcripts, which were more abundant
than the wild type transcript, should be interpreted as a
consequence of the low recognition efficiency of the splicing
machinery for the mutant site, and the use of alternative, lower
affinity, splice sites.
At position 1898, we observed 2 different transcripts in the
absence of mutation. In fact, the activity of the splicing
machinery can certainly be quite versatile, based on differences
in the efficiency of splice site recognition. A very interesting
model suggests that splice sites that may be relatively weak
would be less efficiently recognised than strong splice sites
during elongation of transcription [11]. Hence, if the RNA polII
progresses rapidly, only strong splice sites would be efficiently
recognised, whereas if progression is average or slow, weaker
sites would be correctly recognised, and the exon spliced in. It
can thus be postulated that in the wild type context, the
proportion of the correctly spliced transcript from a normal
Fig. 1. Preparation of CFTR hybrid minigenes. Strategy for engineering CFTR hybrid minigenes from either WT (left panel) or mutant (right panel) genomic DNA.
The minigene structure has been described in [9]. The size of the flanking introns in the minigene is 1038 bp in 5′ and 1126 bp in 3′.
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the mutant, one possibility would be that splice site recognition
would be hampered by proteins that could interact better, or
even in full, with the mutant site, which was very proximal to
the splice site. Such proteins are not likely to be SR proteins, as
ESE finder did not predict a modulation in the binding ability of
SR proteins according to the mutation (one site is predicted for
SRp40 on the TGAAAGG sequence at the end of exon 12, a site
conserved between the wild type and the mutant). Rather, we
can hypothesize that negatively acting proteins, like hnRNP
proteins, could be recruited to hamper normal splicing. This
hypothesis will require further analysis.
From a pathophysiological viewpoint, this study both confirms
previous expectations for the occurrence of a splicing defect in the
case of the 1811+1GNC mutation, and uncovers a striking splicing
defect with the full exclusion of exon 12 in the case of 1898+3GNC.
As observed in the present study, variations in the levels of
the RT-PCR products were obtained between the wild type and
the mutant minigenes. Some of these might be experimental,
although consistently observed. We believe, rather, that the
differences in signal intensities may mainly reflect either the
competition between primer binding sites or the relative
efficiencies of the DNA polymerase over the amplicons that
are partially shared by all the transcripts produced from the
minigenes. This would explain both the lower intensity of themutant transcripts for the 1811+1 GNC mutation, and the higher
intensity of the mutant transcript for the 1898+3 ANG mutation.
In addition, the minigene approach does not allow analyzing
the quantitative defects related to mRNA stability. It can
certainly be expected that the insertion of premature stop
codons, as occurs for both of the studied mutations, could lead
to unstable mRNAs that might be subjected to nonsense mRNA
decay (NMD). By contrast, an increased stability of the mature
mRNAs produced in the context of such genomic mutations that
lead to the insertion of premature STOP codons is not expected.
Nevertheless, what the approach reveals is only the ability of
such pre-mRNAs to be aberrantly spliced because of the
mutations. Consequently, the results of the RT-PCR approach
should be interpreted as fair indicators of the ability of the
aberrant transcripts to encode a CFTR-related polypeptide, were
these stable enough in the patient cells, or no polypeptide at all
if these alternative transcripts are subjected to NMD.
The results obtained with the two experimental strategies,
cloning mutant genomic DNA or site-directed mutagenesis on
WT DNA, were identical. The site-directed mutagenesis
strategy allows the engineering of the mutant minigene in a
couple of days, much faster than the other method. In addition,
the site-directed mutagenesis approach makes it possible to
analyze splicing mutations without DNA samples from patients,
i.e. it can be used both retrospectively and prospectively.
Fig. 2. 1811+1 GNC mutation analysis. a, CFTR hybrid minigenes containing exon 11 and its flanking introns, carrying or not the 1811+1 GNC point mutation, were
transfected into HeLa cells. RT-PCR products were resolved by agarose gel electrophoresis. b, Sequencing of the intron retention fragment (in the middle), compared
to both EDB+1 (upper) and intron 11 WT (lower) sequences. The sequences are shown at the bottom part of the figure, and the used spliced sites are shown within
squares. MUT: The 1811+1 GNC mutation. c, Comparison of the predicted translation product of both WT (upper sequence lane) and 1811+1 GNC (lower sequence
name) mutant transcripts. No RT-PCR product was obtained in mock transfected cells.
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polymorphisms believed to affect splicing. In addition, this
methodology, while directly applicable to DNA sequence
variations that occur in regions where consensus sequences
have been compiled, i.e. in the close vicinity of intron–exon
junctions, should also be useful to analyze the effects of variant
sequences remote from these sites. For example, branch point
mutations or modifications of the polypyrimidine tract in the 3′
region of introns, or any other sequence predicted to affect the
binding of splicing regulatory proteins (like splicing enhancers
or silencers) could also be analyzed. To further validate the
approach, these results could be confronted to the splicingpatterns found in patients or in immortalized cells from patients,
provided that biological samples are available.
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